Jacqueline Natasha Rozman, NPC

Jacqueline Rozman practices at Brunswick Dermatology and Camden Dermatology in Brunswick, Georgia.

Jacqueline Rozman's NPI, 1174912539, was assigned on January 22, 2015. Jacqueline Rozman holds Georgia license RN200773.

Jacqueline Rozman's primary practice is Brunswick Dermatology and Camden Dermatology, at 3008 E Park Ave, Brunswick, GA 31520 in Glynn County. The practice phone is (912) 265-2142.

Jacqueline Rozman's primary practice is Brunswick Dermatology and Camden Dermatology in Brunswick, Georgia. Jacqueline Rozman is also affiliated with Southeast Georgia Health System-Brunswick Campus. The medical group on file is DiPreta Dermatology. Dmand AI also links Jacqueline Rozman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Jacqueline Rozman practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Jacqueline Rozman's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Jacqueline Rozman is licensed in Georgia.

CMS counts 1,100 Medicare patients who saw Jacqueline Rozman in 2024. The largest group is 65 to 74, with 481 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Jacqueline Rozman's median patient age at 76, with 61% women.

In 2024, Jacqueline Rozman wrote 328 Medicare Part D claims for 139 patients. 71% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Jacqueline Rozman for performance year 2024, reported as part of a group. Jacqueline Rozman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 39 general payments to Jacqueline Rozman from 12 drug and device companies in 2025. Food and beverage make up the largest share, 86% of the total. Sanofi and Genzyme US Companies paid the most, $271.